Tumor	B-protein
suppressor	I-protein
proteins	I-protein
as	O
regulators	O
of	O
cell	O
differentiation	O
.	O

The	O
products	O
of	O
the	O
tumor	B-DNA
suppressor	I-DNA
genes	I-DNA
are	O
considered	O
to	O
function	O
as	O
specific	O
inhibitors	O
of	O
tumor	O
cell	O
growth	O
.	O

In	O
this	O
communication	O
,	O
we	O
present	O
evidence	O
to	O
show	O
that	O
these	O
proteins	O
inhibit	O
tumor	O
cell	O
proliferation	O
by	O
participating	O
in	O
the	O
activation	O
of	O
tumor	O
cell	O
differentiation	O
.	O

The	O
ML-1	B-cell_line
human	I-cell_line
myeloblastic	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
used	O
in	O
this	O
study	O
proliferate	O
when	O
treated	O
with	O
insulin-like	B-protein
growth	I-protein
factor	I-protein
I	I-protein
and	O
transferrin	B-protein
but	O
differentiate	O
to	O
monocytes	B-cell_type
when	O
exposed	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
or	O
transforming	B-protein
growth	I-protein
factor	I-protein
beta1	I-protein
,	O
or	O
to	O
macrophage-like	B-cell_type
cells	I-cell_type
when	O
treated	O
with	O
both	O
these	O
cytokines	B-protein
.	O

Initiation	O
of	O
proliferation	O
but	O
not	O
of	O
differentiation	O
was	O
followed	O
by	O
a	O
20-	O
to	O
25-fold	O
increase	O
in	O
the	O
nuclear	O
level	O
of	O
the	O
DNA	B-protein
polymerase-associated	I-protein
processivity	I-protein
factor	I-protein
PCNA	I-protein
and	O
of	O
the	O
proliferation-specific	B-protein
transcription	I-protein
factor	I-protein
E2F1	I-protein
.	O

In	O
contrast	O
,	O
induction	O
of	O
differentiation	O
but	O
not	O
of	O
proliferation	O
was	O
followed	O
by	O
a	O
25-	O
to	O
30-fold	O
increase	O
in	O
the	O
nuclear	O
level	O
of	O
the	O
tumor	B-protein
suppressor	I-protein
proteins	I-protein
p53	I-protein
(	O
wild	O
type	O
)	O
,	O
pRb	B-protein
,	O
and	O
p130/Rb2	B-protein
and	O
of	O
the	O
p53-dependent	B-protein
cyclin	I-protein
kinase	I-protein
inhibitor	I-protein
p21/Cip1	B-protein
.	O

p53	B-protein
and	O
p21/Cip1	B-protein
,	O
respectively	O
,	O
inhibit	O
the	O
expression	O
and	O
activation	O
of	O
PCNA	B-protein
,	O
whereas	O
p130	B-protein
and	O
pRb	B-protein
,	O
respectively	O
,	O
inhibit	O
the	O
expression	O
and	O
activation	O
of	O
E2F1	B-protein
.	O

As	O
a	O
result	O
,	O
G1-S-associated	B-DNA
DNA	I-DNA
and	O
mRNA	O
synthesis	O
is	O
inhibited	O
,	O
growth	O
uncoupled	O
from	O
differentiation	O
,	O
and	O
maturation	O
enabled	O
to	O
proceed	O
.	O

Where	O
this	O
function	O
of	O
the	O
tumor	B-protein
suppressor	I-protein
proteins	I-protein
is	O
impaired	O
,	O
the	O
capacity	O
for	O
differentiation	O
is	O
lost	O
,	O
which	O
leads	O
to	O
the	O
sustained	O
proliferation	O
that	O
is	O
characteristic	O
of	O
the	O
cancer	B-cell_type
cell	I-cell_type
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
58	NULL
,	NULL
4282-4287	NULL
,	NULL
October	NULL
1	NULL
,	NULL
1998	NULL
]	NULL
Advances	NULL
in	NULL
Brief	NULL
Tumor	NULL
Suppressor	NULL
Proteins	NULL
as	NULL
Regulators	NULL
of	NULL
Cell	NULL
Differentiation	NULL
Zhan-Rong	NULL
Li	NULL
,	NULL
Rosemary	NULL
Hromchak	NULL
,	NULL
Anuradha	NULL
Mudipalli	NULL
,	NULL
and	NULL
Alexander	NULL
Bloch	NULL
Roswell	NULL
Park	NULL
Cancer	NULL
Institute	NULL
,	NULL
Buffalo	NULL
,	NULL
New	NULL
York	NULL
14263	NULL
Abstract	NULL
The	NULL
products	NULL
of	NULL
the	NULL
tumor	NULL
suppressor	NULL
genes	NULL
are	NULL
considered	NULL
to	NULL
function	NULL
as	NULL
specific	NULL
inhibitors	NULL
of	NULL
tumor	NULL
cell	NULL
growth	NULL
.	NULL

In	NULL
this	NULL
communication	NULL
,	NULL
we	NULL
present	NULL
evidence	NULL
to	NULL
show	NULL
that	NULL
these	NULL
proteins	NULL
inhibit	NULL
tumor	NULL
cell	NULL
proliferation	NULL
by	NULL
participating	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
tumor	NULL
cell	NULL
differentiation	NULL
.	NULL

The	NULL
ML-1	NULL
human	NULL
myeloblastic	NULL
leukemia	NULL
cells	NULL
used	NULL
in	NULL
this	NULL
study	NULL
proliferate	NULL
when	NULL
treated	NULL
with	NULL
insulin-like	NULL
growth	NULL
factor	NULL
I	NULL
and	NULL
transferrin	NULL
but	NULL
differentiate	NULL
to	NULL
monocytes	NULL
when	NULL
exposed	NULL
to	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
or	NULL
transforming	NULL
growth	NULL
factor	NULL
B1	NULL
,	NULL
or	NULL
to	NULL
macrophage-like	NULL
cells	NULL
when	NULL
treated	NULL
with	NULL
both	NULL
these	NULL
cytokines	NULL
.	NULL

Initiation	NULL
of	NULL
proliferation	NULL
but	NULL
not	NULL
of	NULL
differentiation	NULL
was	NULL
followed	NULL
by	NULL
a	NULL
20-	NULL
to	NULL
25-fold	NULL
increase	NULL
in	NULL
the	NULL
nuclear	NULL
level	NULL
of	NULL
the	NULL
DNA	NULL
polymerase-associated	NULL
processivity	NULL
factor	NULL
PCNA	NULL
and	NULL
of	NULL
the	NULL
proliferation-specific	NULL
transcription	NULL
factor	NULL
E2F1	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
induction	NULL
of	NULL
differentiation	NULL
but	NULL
not	NULL
of	NULL
proliferation	NULL
was	NULL
followed	NULL
by	NULL
a	NULL
25-	NULL
to	NULL
30-fold	NULL
increase	NULL
in	NULL
the	NULL
nuclear	NULL
level	NULL
of	NULL
the	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
p53	NULL
(	NULL
wild	NULL
type	NULL
)	NULL
,	NULL
pRb	NULL
,	NULL
and	NULL
p130/Rb2	NULL
and	NULL
of	NULL
the	NULL
p53-dependent	NULL
cyclin	NULL
kinase	NULL
inhibitor	NULL
p21/Cip1	NULL
.	NULL

p53	NULL
and	NULL
p21/Cip1	NULL
,	NULL
respectively	NULL
,	NULL
inhibit	NULL
the	NULL
expression	NULL
and	NULL
activation	NULL
of	NULL
PCNA	NULL
,	NULL
whereas	NULL
p130	NULL
and	NULL
pRb	NULL
,	NULL
respectively	NULL
,	NULL
inhibit	NULL
the	NULL
expression	NULL
and	NULL
activation	NULL
of	NULL
E2F1	NULL
.	NULL

As	NULL
a	NULL
result	NULL
,	NULL
G	NULL
,	NULL
-S-associated	NULL
DNA	NULL
and	NULL
mRNA	NULL
synthesis	NULL
is	NULL
inhib-ited	NULL
,	NULL
growth	NULL
uncoupled	NULL
from	NULL
differentiation	NULL
,	NULL
and	NULL
maturation	NULL
enabled	NULL
to	NULL
proceed	NULL
.	NULL

Where	NULL
this	NULL
function	NULL
of	NULL
the	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
is	NULL
impaired	NULL
,	NULL
the	NULL
capacity	NULL
for	NULL
differentiation	NULL
is	NULL
lost	NULL
,	NULL
which	NULL
leads	NULL
to	NULL
the	NULL
sustained	NULL
proliferation	NULL
that	NULL
is	NULL
characteristic	NULL
of	NULL
the	NULL
cancer	NULL
cell	NULL
.	NULL

Introduction	NULL
Functionally	NULL
mature	NULL
cells	NULL
that	NULL
are	NULL
formed	NULL
in	NULL
the	NULL
tissues	NULL
of	NULL
an	NULL
organism	NULL
derive	NULL
from	NULL
primitive	NULL
stem	NULL
cells	NULL
that	NULL
,	NULL
along	NULL
discrete	NULL
stages	NULL
of	NULL
development	NULL
,	NULL
differentiate	NULL
to	NULL
their	NULL
fully	NULL
mature	NULL
state	NULL
.	NULL

The	NULL
proportion	NULL
of	NULL
proliferating	NULL
and	NULL
differentiating	NULL
cells	NULL
that	NULL
are	NULL
present	NULL
at	NULL
intermediate	NULL
stages	NULL
of	NULL
the	NULL
maturation	NULL
path	NULL
is	NULL
tightly	NULL
regulated	NULL
to	NULL
assure	NULL
a	NULL
balanced	NULL
supply	NULL
of	NULL
functionally	NULL
competent	NULL
cells	NULL
.	NULL

Regulation	NULL
of	NULL
this	NULL
supply	NULL
is	NULL
mediated	NULL
by	NULL
cytokines	NULL
produced	NULL
by	NULL
cells	NULL
that	NULL
are	NULL
part	NULL
of	NULL
the	NULL
maturation	NULL
sequence	NULL
itself	NULL
or	NULL
that	NULL
belong	NULL
to	NULL
functionally	NULL
related	NULL
developmental	NULL
paths	NULL
.	NULL

If	NULL
maturation	NULL
is	NULL
permanently	NULL
arrested	NULL
at	NULL
an	NULL
intermediate	NULL
stage	NULL
of	NULL
the	NULL
developmental	NULL
sequence	NULL
without	NULL
concomitant	NULL
inhibition	NULL
of	NULL
cell	NULL
proliferation	NULL
,	NULL
a	NULL
population	NULL
of	NULL
morphologically	NULL
and	NULL
functionally	NULL
immature	NULL
``	NULL
cancer	NULL
``	NULL
cells	NULL
accumulates	NULL
,	NULL
which	NULL
interferes	NULL
with	NULL
the	NULL
normal	NULL
functioning	NULL
of	NULL
the	NULL
affected	NULL
organism	NULL
.	NULL

Numerous	NULL
mechanisms	NULL
that	NULL
underlie	NULL
such	NULL
oncogenic	NULL
transformation	NULL
have	NULL
been	NULL
identified	NULL
.	NULL

They	NULL
predominantly	NULL
involve	NULL
alterations	NULL
in	NULL
proliferation-related	NULL
signal	NULL
transduction	NULL
,	NULL
which	NULL
lead	NULL
to	NULL
sustained	NULL
cell	NULL
growth	NULL
without	NULL
cell	NULL
differentiation	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Tumor	NULL
suppressor	NULL
proteins	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
capable	NULL
of	NULL
abolishing	NULL
such	NULL
sustained	NULL
growth	NULL
by	NULL
interfering	NULL
with	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
such	NULL
interference	NULL
having	NULL
been	NULL
considered	NULL
to	NULL
form	NULL
a	NULL
specific	NULL
surveillance	NULL
mechanism	NULL
(	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
this	NULL
study	NULL
,	NULL
we	NULL
provide	NULL
evidence	NULL
to	NULL
show	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
tumor	NULL
Received	NULL
5/20/98	NULL
;	NULL
accepted	NULL
8/13/98	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
study	NULL
was	NULL
aided	NULL
by	NULL
Grant	NULL
CA-36241	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Department	NULL
of	NULL
Health	NULL
and	NULL
Human	NULL
Services	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
Roswell	NULL
Park	NULL
Cancer	NULL
Institute	NULL
,	NULL
Elm	NULL
and	NULL
Carlton	NULL
Streets	NULL
,	NULL
Buffalo	NULL
,	NULL
NY	NULL
14263	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
716	NULL
)	NULL
845-8857.	NULL
cell	NULL
proliferation	NULL
by	NULL
the	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
relates	NULL
to	NULL
their	NULL
role	NULL
as	NULL
natural	NULL
mediators	NULL
of	NULL
cell	NULL
differentiation	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Antibodies	NULL
and	NULL
Reagents	NULL
.	NULL

TGF-G1°	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Bristol-Myers	NULL
Squibb	NULL
(	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
,	NULL
and	NULL
TNF-a	NULL
by	NULL
Asahi	NULL
Chemical	NULL
Industry	NULL
(	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

IGF-I	NULL
was	NULL
purchased	NULL
from	NULL
Austral	NULL
Biologicals	NULL
(	NULL
San	NULL
Ramon	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Antibodies	NULL
to	NULL
PCNA	NULL
(	NULL
PCIO0	NULL
)	NULL
,	NULL
p53	NULL
(	NULL
DO-1	NULL
)	NULL
,	NULL
p21/WAFI/Cipl	NULL
(	NULL
C-19	NULL
)	NULL
,	NULL
pRb	NULL
(	NULL
C-15	NULL
)	NULL
,	NULL
E2F1	NULL
(	NULL
C-20	NULL
)	NULL
,	NULL
p130	NULL
(	NULL
C-20	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
goat	NULL
antimouse	NULL
and	NULL
goat	NULL
antirabbit	NULL
IgG	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
.	NULL
)	NULL

Immobilized	NULL
protein	NULL
A	NULL
was	NULL
purchased	NULL
from	NULL
Pierce	NULL
(	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
,	NULL
and	NULL
the	NULL
molecular	NULL
standards	NULL
used	NULL
in	NULL
SDS-PAGE	NULL
were	NULL
obtained	NULL
from	NULL
Bio-Rad	NULL
Laboratories	NULL
(	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Western	NULL
blotting	NULL
reagents	NULL
were	NULL
supplied	NULL
by	NULL
Amersham	NULL
International	NULL
(	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

The	NULL
phosphorothioate-mod-ified	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
pRb	NULL
,	NULL
5-GGG	NULL
GGT	NULL
TTT	NULL
GGG	NULL
CGG	NULL
CAT	NULL
GAC-3	NULL
'	NULL
(	NULL
3	NULL
)	NULL
;	NULL
to	NULL
p53	NULL
,	NULL
5-CGG	NULL
CTC	NULL
CTC	NULL
CAT	NULL
GGC	NULL
AGT-3	NULL
'	NULL
(	NULL
4	NULL
)	NULL
;	NULL
and	NULL
to	NULL
a	NULL
segment	NULL
of	NULL
the	NULL
p130	NULL
promoter	NULL
,	NULL
5-CGA	NULL
CGG	NULL
CAT	NULL
AGC	NULL
GCA	NULL
CCC	NULL
CT-3	NULL
``	NULL
(	NULL
5	NULL
)	NULL
;	NULL
and	NULL
their	NULL
sense	NULL
oligonucleotides	NULL
were	NULL
synthesized	NULL
by	NULL
the	NULL
Roswell	NULL
Park	NULL
Cancer	NULL
Institute	NULL
Biopolymer	NULL
Facility	NULL
.	NULL

SuperFect	NULL
transfection	NULL
reagent	NULL
was	NULL
supplied	NULL
by	NULL
Qiagen	NULL
,	NULL
Inc.	NULL
(	NULL
Chatsworth	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

PCNA-promoter	NULL
and	NULL
E2F1-promoter	NULL
DNA	NULL
was	NULL
provided	NULL
to	NULL
us	NULL
,	NULL
respectively	NULL
,	NULL
by	NULL
Dr.	NULL
Swati	NULL
P.	NULL
Deb	NULL
(	NULL
University	NULL
of	NULL
Texas	NULL
Health	NULL
Science	NULL
Center	NULL
,	NULL
San	NULL
Antonio	NULL
,	NULL
TX	NULL
;	NULL
Ref	NULL
.	NULL

6	NULL
)	NULL
,	NULL
and	NULL
Dr.	NULL
David	NULL
G.	NULL
Johnson	NULL
(	NULL
The	NULL
University	NULL
of	NULL
Texas	NULL
M.	NULL
D.	NULL
Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
Smithville	NULL
,	NULL
TX	NULL
;	NULL
Ref	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Cell	NULL
Cultures	NULL
.	NULL

ML-1	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
FBS	NULL
.	NULL

Cultures	NULL
containing	NULL
5	NULL
X	NULL
10°	NULL
cells/ml	NULL
were	NULL
grown	NULL
in	NULL
this	NULL
medium	NULL
for	NULL
3	NULL
days	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
.	NULL

Fresh	NULL
medium	NULL
was	NULL
then	NULL
added	NULL
to	NULL
reduce	NULL
the	NULL
cell	NULL
number	NULL
to	NULL
the	NULL
starting	NULL
concentration	NULL
.	NULL

To	NULL
perform	NULL
the	NULL
assays	NULL
described	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
synchronized	NULL
in	NULL
G	NULL
,	NULL
,	NULL
by	NULL
incubation	NULL
for	NULL
3	NULL
days	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
0.05	NULL
%	NULL
FBS	NULL
.	NULL

After	NULL
washing	NULL
with	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
cells/ml	NULL
were	NULL
suspended	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
0.5	NULL
%	NULL
FBS	NULL
,	NULL
which	NULL
was	NULL
added	NULL
to	NULL
preserve	NULL
their	NULL
viability	NULL
during	NULL
the	NULL
prolonged	NULL
(	NULL
70	NULL
h	NULL
)	NULL
assay	NULL
period	NULL
.	NULL

Proliferation	NULL
of	NULL
the	NULL
cells	NULL
was	NULL
initiated	NULL
by	NULL
treatment	NULL
with	NULL
40	NULL
ng/ml	NULL
IGF-I	NULL
plus	NULL
0.5	NULL
ug/ml	NULL
Tf	NULL
;	NULL
monocytic	NULL
differentiation	NULL
was	NULL
induced	NULL
with	NULL
60	NULL
ng/ml	NULL
TGF-B1	NULL
or	NULL
with	NULL
20	NULL
units/ml	NULL
TNF-a	NULL
;	NULL
and	NULL
macrophage-like	NULL
cells	NULL
were	NULL
obtained	NULL
by	NULL
adding	NULL
10	NULL
ng/ml	NULL
TGF-B1	NULL
together	NULL
with	NULL
10	NULL
units/ml	NULL
TNF-a	NULL
.	NULL

The	NULL
number	NULL
of	NULL
cells	NULL
obtained	NULL
under	NULL
these	NULL
conditions	NULL
was	NULL
counted	NULL
by	NULL
hemocytometer	NULL
and	NULL
their	NULL
viability	NULL
assayed	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
;	NULL
the	NULL
extent	NULL
of	NULL
differentiation	NULL
was	NULL
assessed	NULL
by	NULL
determining	NULL
the	NULL
mature	NULL
phenotype	NULL
.	NULL

Nuclear	NULL
and	NULL
Cytoplasmic	NULL
Extracts	NULL
.	NULL

To	NULL
obtain	NULL
nuclei	NULL
,	NULL
2-5	NULL
X	NULL
10	NULL
'	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
serum-free	NULL
,	NULL
ice-cold	NULL
RPMI	NULL
1640	NULL
,	NULL
followed	NULL
by	NULL
suspension	NULL
in	NULL
0.3	NULL
mi	NULL
of	NULL
nuclear	NULL
buffer	NULL
consisting	NULL
of	NULL
2	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
5	NULL
mm	NULL
K	NULL
,	NULL
HPO	NULL
,	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
PMSF	NULL
,	NULL
20	NULL
ug/mi	NULL
aprotinin	NULL
,	NULL
20	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
and	NULL
0.1	NULL
mm	NULL
Na	NULL
,	NULL
;	NULL
VO	NULL
,	NULL
.	NULL

An	NULL
additional	NULL
0.3	NULL
ml	NULL
of	NULL
nuclear	NULL
buffer	NULL
containing	NULL
0.7	NULL
%	NULL
of	NULL
Triton	NULL
X-100	NULL
was	NULL
then	NULL
added	NULL
;	NULL
after	NULL
standing	NULL
on	NULL
ice	NULL
for	NULL
8	NULL
min	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
homogenized	NULL
,	NULL
and	NULL
the	NULL
homogenate	NULL
centrifuged	NULL
at	NULL
800	NULL
rpm	NULL
,	NULL
the	NULL
supernatantnt	NULL
being	NULL
designated	NULL
the	NULL
cytoplasmic	NULL
fraction	NULL
.	NULL

The	NULL
pellet	NULL
was	NULL
washed	NULL
once	NULL
with	NULL
nuclear	NULL
buffer	NULL
,	NULL
and	NULL
the	NULL
nuclear	NULL
extract	NULL
was	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
buffer	NULL
containing	NULL
20	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
0.42	NULL
m	NULL
NaCl	NULL
,	NULL
1.5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mm	NULL
EDTA	NULL
,	NULL
0.5	NULL
mm	NULL
PMSF	NULL
,	NULL
0.5	NULL
mm	NULL
DTT	NULL
,	NULL
0.1	NULL
mm	NULL
Na	NULL
;	NULL
VO,4	NULL
,	NULL
50	NULL
mm	NULL
NaF	NULL
,	NULL
30	NULL
mM	NULL
PP	NULL
;	NULL
,	NULL
20	NULL
pg/ml	NULL
leupeptin	NULL
,	NULL
and	NULL
20	NULL
ug/ml	NULL
aprotinin	NULL
;	NULL
homogenization	NULL
was	NULL
carried	NULL
out	NULL
using	NULL
a	NULL
Kontes	NULL
Duall	NULL
tissue	NULL
grinder	NULL
.	NULL

After	NULL
centrifugation	NULL
of	NULL
the	NULL
homogenate	NULL
,	NULL
the	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
TGF-B1	NULL
,	NULL
transforming	NULL
growth	NULL
factor	NULL
B1	NULL
;	NULL
TNF-a	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
;	NULL
IGF-I	NULL
,	NULL
insulin-like	NULL
growth	NULL
factor	NULL
I	NULL
;	NULL
Tf	NULL
,	NULL
transferrin	NULL
;	NULL
PCNA	NULL
,	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
;	NULL
FBS	NULL
,	NULL
fetal	NULL
bovine	NULL
serum	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
PMSF	NULL
,	NULL
phenylmethylsulfonylfluoride	NULL
;	NULL
pRB	NULL
,	NULL
retinoblastoma	NULL
protein	NULL
;	NULL
DF	NULL
,	NULL
differentiation	NULL
factor	NULL
.	NULL

4282	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

DIFFERENTIATION	NULL
REGULATORS	NULL
supernatant-designated	NULL
the	NULL
nuclear	NULL
extract-was	NULL
frozen	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Western	NULL
Blotting	NULL
and	NULL
Immunoprecipitation	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
p130	NULL
,	NULL
p53	NULL
,	NULL
pRB	NULL
,	NULL
p21/Cip	NULL
,	NULL
PCNA	NULL
,	NULL
and	NULL
E2F1	NULL
in	NULL
the	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
fractions	NULL
were	NULL
assayed	NULL
by	NULL
Western	NULL
blotting	NULL
,	NULL
and	NULL
immune	NULL
complexes	NULL
were	NULL
detected	NULL
by	NULL
immunoprecipitation	NULL
followed	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
nuclear	NULL
or	NULL
cytoplasmic	NULL
extract	NULL
(	NULL
300	NULL
ug	NULL
of	NULL
protein	NULL
)	NULL
was	NULL
added	NULL
to	NULL
300	NULL
pl	NULL
of	NULL
immunoprecipitation	NULL
buffer	NULL
containing	NULL
50	NULL
mm	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
150	NULL
mm	NULL
NaCl	NULL
,	NULL
0.5	NULL
%	NULL
NP4Q	NULL
,	NULL
20	NULL
mm	NULL
EDTA	NULL
,	NULL
0.1	NULL
mM	NULL
Na	NULL
;	NULL
VO	NULL
,	NULL
,	NULL
50	NULL
mm	NULL
NaF	NULL
,	NULL
1	NULL
mm	NULL
PMSF	NULL
,	NULL
1	NULL
mm	NULL
benzamidine	NULL
,	NULL
10	NULL
g/m	NULL
]	NULL
trypsin	NULL
inhibitor	NULL
,	NULL
20	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
and	NULL
20	NULL
ug/ml	NULL
aprotinin	NULL
.	NULL

To	NULL
each	NULL
sample	NULL
,	NULL
1.5	NULL
ug	NULL
of	NULL
the	NULL
desired	NULL
affinity-purified	NULL
antibody	NULL
was	NULL
added	NULL
.	NULL

After	NULL
rotating	NULL
at	NULL
4°C	NULL
for	NULL
1	NULL
h	NULL
,	NULL
40	NULL
wl	NULL
of	NULL
immobilized	NULL
protein	NULL
A	NULL
was	NULL
added	NULL
to	NULL
each	NULL
sample	NULL
,	NULL
and	NULL
rotation	NULL
continued	NULL
overnight	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
,	NULL
and	NULL
after	NULL
washing	NULL
,	NULL
the	NULL
immunecomplexes	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Measurement	NULL
of	NULL
DNA	NULL
Synthesis	NULL
and	NULL
Rapidly	NULL
Turning-over	NULL
mRNA	NULL
.	NULL

DNA	NULL
synthesis	NULL
was	NULL
determined	NULL
by	NULL
methyl-	NULL
[	NULL
°HJthymidine	NULL
incorporation	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Rapidly	NULL
turning	NULL
over	NULL
mRNA	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
labeled	NULL
for	NULL
1	NULL
h	NULL
with	NULL
5-	NULL
[	NULL
*HJuridine	NULL
(	NULL
20	NULL
uCi/ml	NULL
,	NULL
23.6	NULL
Ci/mmol	NULL
)	NULL
,	NULL
and	NULL
RNA	NULL
was	NULL
extracted	NULL
with	NULL
a	NULL
concentrated	NULL
solution	NULL
of	NULL
Nal	NULL
,	NULL
mRNA	NULL
being	NULL
selectively	NULL
bound	NULL
to	NULL
nitrocellulose	NULL
paper	NULL
.	NULL

H-labeled	NULL
mRNA	NULL
was	NULL
then	NULL
counted	NULL
by	NULL
liquid	NULL
scintillation	NULL
spectrometer	NULL
.	NULL

EMSA	NULL
.	NULL

For	NULL
determining	NULL
p53	NULL
binding	NULL
to	NULL
the	NULL
PCNA	NULL
promoter	NULL
,	NULL
PCNA	NULL
promoter	NULL
DNA	NULL
was	NULL
cut	NULL
with	NULL
HindIII	NULL
,	NULL
and	NULL
the	NULL
segment	NULL
-272	NULL
to	NULL
-46	NULL
was	NULL
isolated	NULL
as	NULL
described	NULL
(	NULL
6	NULL
)	NULL
.	NULL

The	NULL
fragment	NULL
was	NULL
end-labeled	NULL
with	NULL
*°P	NULL
using	NULL
T4	NULL
polynucle-otide	NULL
kinase	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
protein	NULL
and	NULL
the	NULL
labeled	NULL
PCNA	NULL
promoter	NULL
DNA	NULL
fragment	NULL
(	NULL
50,000	NULL
cpm	NULL
)	NULL
in	NULL
binding	NULL
buffer	NULL
consisting	NULL
of	NULL
10	NULL
mm	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
50	NULL
mm	NULL
NaCl	NULL
,	NULL
1	NULL
mm	NULL
DTT	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
%	NULL
(	NULL
viv	NULL
)	NULL
glycerol	NULL
,	NULL
and	NULL
1.5	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
25	NULL
wl	NULL
.	NULL

The	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
at	NULL
room	NULL
temparature	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
electrophoresed	NULL
at	NULL
175	NULL
V	NULL
on	NULL
5	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gel	NULL
with	NULL
0.5	NULL
m	NULL
Tris-borate/EDTA	NULL
buffer	NULL
.	NULL

Specificity	NULL
of	NULL
binding	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
50	NULL
%	NULL
unlabeled	NULL
probe	NULL
.	NULL

p53	NULL
in	NULL
the	NULL
complex	NULL
was	NULL
identified	NULL
by	NULL
incubating	NULL
the	NULL
reaction	NULL
mixtures	NULL
with	NULL
1.5	NULL
ug	NULL
of	NULL
anti-p53	NULL
antibody	NULL
for	NULL
30	NULL
min	NULL
(	NULL
supershift	NULL
reaction	NULL
)	NULL
.	NULL

EMSA	NULL
was	NULL
also	NULL
used	NULL
to	NULL
determine	NULL
p130-E2F1	NULL
promoter	NULL
binding	NULL
.	NULL

The	NULL
pGL3	NULL
E2F1	NULL
promoter	NULL
DNA	NULL
(	NULL
7	NULL
)	NULL
was	NULL
digested	NULL
with	NULL
Eagl	NULL
,	NULL
and	NULL
the	NULL
101-bp	NULL
segment-purified	NULL
by	NULL
agarose	NULL
gel-was	NULL
end-labeled	NULL
with	NULL
*°P	NULL
.	NULL

Specificity	NULL
of	NULL
binding	NULL
was	NULL
confirmed	NULL
by	NULL
adding	NULL
75	NULL
%	NULL
unlabeled	NULL
probe	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
,	NULL
and	NULL
antibody	NULL
to	NULL
p130	NULL
was	NULL
used	NULL
to	NULL
detect	NULL
the	NULL
presence	NULL
of	NULL
p130	NULL
in	NULL
the	NULL
complex	NULL
.	NULL

Effect	NULL
of	NULL
Antisense	NULL
Oligonucleotides	NULL
of	NULL
p53	NULL
,	NULL
p130	NULL
,	NULL
and	NULL
pRb	NULL
on	NULL
ML-1	NULL
Cell	NULL
Differentiation	NULL
.	NULL

Ten	NULL
,	NULL
5	NULL
,	NULL
and	NULL
20	NULL
ug	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
the	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
p53	NULL
,	NULL
p130	NULL
,	NULL
and	NULL
pRb	NULL
were	NULL
incubated	NULL
with	NULL
2	NULL
pl	NULL
superFect	NULL
at	NULL
37°C	NULL
for	NULL
15	NULL
min	NULL
,	NULL
diluted	NULL
with	NULL
100	NULL
pl	NULL
of	NULL
serum-free	NULL
medium	NULL
,	NULL
and	NULL
added	NULL
to	NULL
1	NULL
mi	NULL
of	NULL
cell	NULL
suspension	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
containing	NULL
10	NULL
ng/ml	NULL
TGF-B1	NULL
and	NULL
10	NULL
units/ml	NULL
TNF-a	NULL
.	NULL

Corresponding	NULL
sense	NULL
oligonucleotides	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
.	NULL

After	NULL
2	NULL
days	NULL
of	NULL
incubation	NULL
,	NULL
the	NULL
cell	NULL
number	NULL
was	NULL
counted	NULL
and	NULL
the	NULL
extent	NULL
of	NULL
differentiation	NULL
determined	NULL
.	NULL

Results	NULL
and	NULL
Discussion	NULL
ML-1	NULL
human	NULL
myeloblastic	NULL
leukemia	NULL
cells	NULL
(	NULL
10	NULL
)	NULL
,	NULL
suspended	NULL
in	NULL
se-rum-depleted	NULL
RPMI	NULL
1640	NULL
,	NULL
proliferate	NULL
when	NULL
treated	NULL
with	NULL
IGF-I	NULL
plus	NULL
Tf	NULL
(	NULL
Fig	NULL
.	NULL

1a	NULL
)	NULL
but	NULL
differentiate	NULL
to	NULL
monocytes	NULL
when	NULL
exposed	NULL
to	NULL
TGF-BI1	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
)	NULL
or	NULL
to	NULL
TNF-a	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Macrophage-like	NULL
cells	NULL
are	NULL
formed	NULL
when	NULL
these	NULL
two	NULL
cytokines	NULL
are	NULL
applied	NULL
jointly	NULL
(	NULL
Fig	NULL
.	NULL

lc	NULL
)	NULL
.	NULL

By	NULL
adding	NULL
0.5	NULL
%	NULL
FBS	NULL
to	NULL
these	NULL
cultures	NULL
,	NULL
their	NULL
long-term	NULL
(	NULL
>	NULL
48	NULL
h	NULL
)	NULL
viability	NULL
is	NULL
enhanced	NULL
without	NULL
their	NULL
maturation	NULL
status	NULL
being	NULL
affected	NULL
.	NULL

When	NULL
treated	NULL
with	NULL
60	NULL
ng/ml	NULL
of	NULL
TGF-B1	NULL
or	NULL
with	NULL
20	NULL
units/ml	NULL
of	NULL
TNF-a	NULL
,	NULL
~85-90	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
convert	NULL
to	NULL
monocytes	NULL
(	NULL
Fig	NULL
.	NULL

16	NULL
)	NULL
.	NULL

When	NULL
both	NULL
these	NULL
cytokines	NULL
are	NULL
applied	NULL
(	NULL
10	NULL
ng/ml	NULL
TGF-B1	NULL
and	NULL
10	NULL
units/ml	NULL
TNFa	NULL
)	NULL
,	NULL
90-95	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
mature	NULL
to	NULL
macrophage-like	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1c	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
proliferation	NULL
leads	NULL
the	NULL
cell	NULL
population	NULL
to	NULL
double	NULL
after	NULL
approximately	NULL
70	NULL
h	NULL
of	NULL
incubation	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
,	NULL
whereas	NULL
induction	NULL
of	NULL
differentiation	NULL
results	NULL
in	NULL
cessation	NULL
of	NULL
cell	NULL
growth	NULL
.	NULL

Because	NULL
the	NULL
0.5	NULL
%	NULL
amount	NULL
of	NULL
FBS	NULL
that	NULL
is	NULL
added	NULL
to	NULL
the	NULL
RPMI	NULL
1640	NULL
to	NULL
enhance	NULL
viability	NULL
contains	NULL
a	NULL
small	NULL
amount	NULL
of	NULL
IGF-I	NULL
and	NULL
Tf	NULL
,	NULL
~15	NULL
%	NULL
-20	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
controls	NULL
are	NULL
able	NULL
to	NULL
proliferate	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

This	NULL
amount	NULL
of	NULL
FBS	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
number	NULL
of	NULL
differentiation-induced	NULL
cells	NULL
.	NULL

Because	NULL
induction	NULL
of	NULL
ML-1	NULL
cell	NULL
differentiation	NULL
is	NULL
accompanied	NULL
by	NULL
proliferation	NULL
arrest	NULL
at	NULL
the	NULL
G	NULL
,	NULL
-S	NULL
border	NULL
(	NULL
8	NULL
)	NULL
,	NULL
we	NULL
began	NULL
an	NULL
examination	NULL
of	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
this	NULL
proliferation-arrest	NULL
is	NULL
regulated	NULL
.	NULL

We	NULL
,	NULL
first	NULL
,	NULL
focused	NULL
our	NULL
attention	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
PCNA	NULL
(	NULL
11	NULL
)	NULL
and	NULL
E2F1	NULL
(	NULL
12	NULL
)	NULL
,	NULL
two	NULL
key	NULL
mediators	NULL
of	NULL
the	NULL
proliferation-associated	NULL
G	NULL
,	NULL
-S	NULL
transit	NULL
.	NULL

Because	NULL
the	NULL
level	NULL
of	NULL
these	NULL
mediators	NULL
,	NULL
like	NULL
that	NULL
of	NULL
other	NULL
regulatory	NULL
proteins	NULL
,	NULL
varies	NULL
as	NULL
the	NULL
cells	NULL
progress	NULL
along	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
all	NULL
cell	NULL
populations	NULL
used	NULL
in	NULL
these	NULL
assays	NULL
were	NULL
synchronized	NULL
in	NULL
G	NULL
,	NULL
by	NULL
serum	NULL
depletion	NULL
(	NULL
13	NULL
)	NULL
.	NULL

This	NULL
modification	NULL
assured	NULL
that	NULL
the	NULL
results	NULL
obtained	NULL
derived	NULL
from	NULL
an	NULL
essentially	NULL
homogeneous	NULL
cell	NULL
population	NULL
,	NULL
rather	NULL
than	NULL
from	NULL
mixed	NULL
populations	NULL
containing	NULL
cells	NULL
present	NULL
at	NULL
multiple	NULL
stages	NULL
of	NULL
cell	NULL
growth	NULL
or	NULL
differentiation	NULL
.	NULL

Because	NULL
such	NULL
regulatory	NULL
proteins	NULL
can	NULL
be	NULL
present	NULL
at	NULL
different	NULL
levels	NULL
and	NULL
in	NULL
different	NULL
molecular	NULL
forms	NULL
in	NULL
nuclei	NULL
as	NULL
compared	NULL
to	NULL
cytoplasm	NULL
,	NULL
separation	NULL
of	NULL
the	NULL
two	NULL
compartments	NULL
was	NULL
also	NULL
carried	NULL
out	NULL
routinely	NULL
to	NULL
allow	NULL
an	NULL
accurate	NULL
assessment	NULL
of	NULL
the	NULL
site	NULL
(	NULL
s	NULL
)	NULL
at	NULL
which	NULL
these	NULL
proteins	NULL
exert	NULL
their	NULL
primary	NULL
activity	NULL
unimpeded	NULL
by	NULL
artifacts	NULL
that	NULL
may	NULL
result	NULL
from	NULL
intermixing	NULL
the	NULL
components	NULL
of	NULL
different	NULL
cell	NULL
compartments	NULL
.	NULL

Employing	NULL
these	NULL
assay	NULL
conditions	NULL
,	NULL
we	NULL
found	NULL
that	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2a	NULL
,	NULL
the	NULL
level	NULL
of	NULL
the	NULL
PCNA	NULL
was	NULL
low	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
control	NULL
as	NULL
well	NULL
as	NULL
of	NULL
proliferation-	NULL
and	NULL
differentiation-induced	NULL
ML-1	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2b	NULL
,	NULL
an	NULL
approximately	NULL
20-fold	NULL
increase	NULL
in	NULL
the	NULL
level	NULL
of	NULL
PCNA	NULL
occurred	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
proliferation-stimulated	NULL
cells	NULL
.	NULL

(	NULL
d	NULL
)	NULL
117.5	NULL
Nl	NULL
;	NULL
€	NULL
-	NULL
15.0	NULL
2	NULL
-	NULL
C5	NULL
442.50	NULL
.	NULL

©	NULL
7	NULL
.A	NULL
-	NULL
10.0	NULL
E	NULL
|	NULL
3	NULL
p-4	NULL
17.4	NULL
-	NULL
Z	NULL
|	NULL
%	NULL
U	NULL
so	NULL
9	NULL
0	NULL
20	NULL
40	NULL
60	NULL
80	NULL
(	NULL
n	NULL
)	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Morphology	NULL
of	NULL
ML-1	NULL
human	NULL
myeloblastic	NULL
leukemia	NULL
cells	NULL
stimulated	NULL
to	NULL
proliferate	NULL
with	NULL
IGF-I	NULL
and	NULL
Tf	NULL
(	NULL
a	NULL
)	NULL
or	NULL
to	NULL
differentiate	NULL
to	NULL
monocytes	NULL
with	NULL
TGF-B1	NULL
(	NULL
b	NULL
)	NULL
or	NULL
macrophage-like	NULL
cells	NULL
with	NULL
TGF-B1	NULL
+	NULL
TNF-a	NULL
(	NULL
c	NULL
)	NULL
.	NULL

The	NULL
time-dependent	NULL
change	NULL
in	NULL
the	NULL
number	NULL
of	NULL
unstimulated	NULL
(	NULL
0	NULL
)	NULL
,	NULL
proliferation-stimulated	NULL
(	NULL
@	NULL
)	NULL
,	NULL
or	NULL
differentiation-induced	NULL
cells	NULL
(	NULL
C	NULL
]	NULL
)	NULL
is	NULL
shown	NULL
in	NULL
(	NULL
d	NULL
)	NULL
.	NULL

The	NULL
data	NULL
points	NULL
shown	NULL
in	NULL
Fig.1d	NULL
represent	NULL
the	NULL
mean	NULL
+	NULL
SD	NULL
derived	NULL
from	NULL
five	NULL
separate	NULL
experiments	NULL
.	NULL

4283	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

DIFFERENTIATION	NULL
REGULATORS	NULL
40	NULL
(	NULL
a	NULL
)	NULL
PCNA	NULL
;	NULL
|	NULL
(	NULL
b	NULL
)	NULL
PCNA	NULL
;	NULL
nuclear	NULL
(	NULL
c	NULL
)	NULL
DNA	NULL
f	NULL
cytoplasmic	NULL
[	NULL
30	NULL
-	NULL
H	NULL
«	NULL
ami-	NULL
PCNA	NULL
aim	NULL
»	NULL
«	NULL
-|-PCNA	NULL
(	NULL
36	NULL
KD	NULL
)	NULL
(	NULL
36	NULL
KD	NULL
)	NULL
20	NULL
L	NULL
6	NULL
P	NULL
-	NULL
G6	NULL
D	NULL
/*	NULL
~	NULL
}	NULL
bud	NULL
10	NULL
|-	NULL
H	NULL
/	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Time-dependent	NULL
change	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
PCNA	NULL
irs	NULL
AD	NULL
-0	NULL
_o	NULL
(	NULL
a	NULL
,	NULL
b	NULL
)	NULL
and	NULL
E2F1	NULL
(	NULL
d	NULL
,	NULL
e	NULL
)	NULL
proteins	NULL
present	NULL
in	NULL
the	NULL
cytoplasm	NULL
g	NULL
and	NULL
nuclei	NULL
of	NULL
untreated	NULL
(	NULL
0	NULL
)	NULL
,	NULL
proliferation-stimulated	NULL
(	NULL
@	NULL
)	NULL
,	NULL
0	NULL
0	NULL
I	NULL
or	NULL
differentiation-induced	NULL
(	NULL
C	NULL
]	NULL
)	NULL
ML-1	NULL
cells	NULL
,	NULL
as	NULL
related	NULL
to	NULL
__	NULL
--	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
so	NULL
60	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
the	NULL
extent	NULL
of	NULL
DNA	NULL
(	NULL
c	NULL
)	NULL
and	NULL
mRNA	NULL
synthesis	NULL
(	NULL
f	NULL
)	NULL
occurring	NULL
o	NULL
40	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

All	NULL
values	NULL
shown	NULL
in	NULL
the	NULL
panels	NULL
a	NULL
,	NULL
b	NULL
,	NULL
d	NULL
,	NULL
and	NULL
__	NULL
_	NULL
>	NULL
(	NULL
d	NULL
)	NULL
E2F1	NULL
;	NULL
cytoplasmic	NULL
(	NULL
e	NULL
)	NULL
E2F1	NULL
;	NULL
nuclear	NULL
(	NULL
8	NULL
)	NULL
mRNA	NULL
e	NULL
were	NULL
determined	NULL
by	NULL
Western	NULL
blots	NULL
normalized	NULL
to	NULL
0-time	NULL
_	NULL
+	NULL
f	NULL
F	NULL
control	NULL
.	NULL

The	NULL
data	NULL
given	NULL
in	NULL
the	NULL
panels	NULL
are	NULL
representative	NULL
of	NULL
__	NULL
2	NULL
30	NULL
els	NULL
three	NULL
separate	NULL
experiments	NULL
each	NULL
.	NULL

The	NULL
insets	NULL
given	NULL
in	NULL
the	NULL
l	NULL
-	NULL
|-E2F1	NULL
-	NULL
ee	NULL
*	NULL
~-E2F1	NULL
panels	NULL
show	NULL
peak	NULL
levels	NULL
of	NULL
the	NULL
respective	NULL
proteins	NULL
in	NULL
_	NULL
C	NULL
(	NULL
60	NULL
KD	NULL
)	NULL
I	NULL
(	NULL
60	NULL
kp	NULL
)	NULL
growth	NULL
(	NULL
G	NULL
)	NULL
and	NULL
differentiation	NULL
(	NULL
D	NULL
)	NULL
.	NULL

[	NULL
6	NULL
0	NULL
f	NULL
6	NULL
D	NULL
20	NULL
10	NULL
-	NULL
Lr	NULL
Ls	NULL
_L	NULL
i_	NULL
]	NULL
0	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
o	NULL
The	NULL
level	NULL
of	NULL
this	NULL
processivity	NULL
factor	NULL
remained	NULL
low	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
control	NULL
cells	NULL
and	NULL
of	NULL
differentiation-induced	NULL
cells	NULL
.	NULL

In	NULL
keeping	NULL
with	NULL
the	NULL
determinant	NULL
role	NULL
PCNA	NULL
plays	NULL
in	NULL
DNA	NULL
synthesis	NULL
(	NULL
11	NULL
)	NULL
,	NULL
the	NULL
pronounced	NULL
difference	NULL
in	NULL
the	NULL
level	NULL
at	NULL
which	NULL
this	NULL
protein	NULL
was	NULL
expressed	NULL
in	NULL
growth	NULL
versus	NULL
differentiation	NULL
(	NULL
Fig	NULL
.	NULL

2b	NULL
)	NULL
was	NULL
reflected	NULL
in	NULL
the	NULL
extent	NULL
to	NULL
which	NULL
DNA	NULL
synthesis	NULL
took	NULL
place	NULL
in	NULL
proliferation-stimulated	NULL
as	NULL
compared	NULL
to	NULL
control	NULL
cells	NULL
or	NULL
to	NULL
differentiation-induced	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2¢c	NULL
)	NULL
.	NULL

Extensive	NULL
DNA	NULL
synthesis	NULL
occurred	NULL
only	NULL
in	NULL
growth-induced	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
control	NULL
or	NULL
in	NULL
differentiation-induced	NULL
cells	NULL
.	NULL

In	NULL
parallel	NULL
with	NULL
PCNA	NULL
,	NULL
the	NULL
transcription	NULL
factor	NULL
E2F1	NULL
was	NULL
present	NULL
at	NULL
only	NULL
a	NULL
very	NULL
low	NULL
level	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
control	NULL
as	NULL
well	NULL
as	NULL
of	NULL
growth-and	NULL
differentiation-induced	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
this	NULL
transcription	NULL
factor	NULL
was	NULL
expressed	NULL
at	NULL
a	NULL
high	NULL
level	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
proliferation-induced	NULL
cells	NULL
(	NULL
Fig	NULL
,	NULL
2¢	NULL
)	NULL
,	NULL
its	NULL
concentration	NULL
being	NULL
low	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
control	NULL
and	NULL
of	NULL
differentiation-stimulated	NULL
cells	NULL
.	NULL

EZF1	NULL
regulates	NULL
the	NULL
transcription	NULL
of	NULL
various	NULL
genes	NULL
required	NULL
for	NULL
the	NULL
proliferation-associated	NULL
G	NULL
,	NULL
-	NULL
$	NULL
transit	NULL
(	NULL
12	NULL
)	NULL
,	NULL
and	NULL
the	NULL
difference	NULL
in	NULL
level	NULL
at	NULL
which	NULL
E2F1	NULL
is	NULL
present	NULL
in	NULL
growth	NULL
as	NULL
compared	NULL
to	NULL
differentiation	NULL
is	NULL
,	NULL
thus	NULL
,	NULL
expected	NULL
to	NULL
affect	NULL
the	NULL
extent	NULL
of	NULL
transcription	NULL
that	NULL
ensues	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2f	NULL
,	NULL
E2F1-mediated	NULL
mRNA	NULL
synthesis	NULL
was	NULL
,	NULL
indeed	NULL
,	NULL
high	NULL
in	NULL
growth	NULL
and	NULL
very	NULL
low	NULL
in	NULL
differentiation	NULL
.	NULL

These	NULL
data	NULL
were	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
findings	NULL
demonstrating	NULL
that	NULL
PCNA	NULL
and	NULL
E2F1	NULL
serve	NULL
,	NULL
respectively	NULL
,	NULL
as	NULL
determinants	NULL
of	NULL
DNA	NULL
and	NULL
mRNA	NULL
synthesis	NULL
required	NULL
for	NULL
the	NULL
proliferation-associated	NULL
cell	NULL
cycle	NULL
transit	NULL
from	NULL
G	NULL
,	NULL
to	NULL
S-phase	NULL
.	NULL

Their	NULL
lack	NULL
of	NULL
expression	NULL
in	NULL
differentiation	NULL
,	NULL
thus	NULL
,	NULL
provided	NULL
a	NULL
mechanistic	NULL
basis	NULL
for	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
G	NULL
,	NULL
-S	NULL
transit	NULL
in	NULL
the	NULL
maturation	NULL
process	NULL
.	NULL

This	NULL
recognition	NULL
raised	NULL
questions	NULL
,	NULL
concerning	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
the	NULL
expression	NULL
and	NULL
activation	NULL
of	NULL
PCNA	NULL
and	NULL
E2F1	NULL
was	NULL
regulated	NULL
.	NULL

As	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
various	NULL
reports	NULL
had	NULL
shown	NULL
that	NULL
the	NULL
level	NULL
and	NULL
activity	NULL
of	NULL
PCNA	NULL
and	NULL
E2F1	NULL
is	NULL
controlled	NULL
by	NULL
diverse	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
.	NULL

Thus	NULL
,	NULL
wild-type	NULL
p53	NULL
,	NULL
present	NULL
in	NULL
ML-1	NULL
cells	NULL
(	NULL
14	NULL
)	NULL
,	NULL
was	NULL
reported	NULL
able	NULL
to	NULL
interfere	NULL
with	NULL
PCNA	NULL
synthesis	NULL
by	NULL
repressing	NULL
the	NULL
PCNA	NULL
promoter	NULL
(	NULL
15-17	NULL
)	NULL
.	NULL

p53	NULL
was	NULL
also	NULL
shown	NULL
capable	NULL
of	NULL
regulating	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
cyclin	NULL
kinase	NULL
inhibitor	NULL
p21/Cipl/Waf/l	NULL
via	NULL
a	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
50	NULL
p	NULL
1q	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
p21	NULL
promoter	NULL
(	NULL
18	NULL
)	NULL
.	NULL

p21/Cip1	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
was	NULL
observed	NULL
able	NULL
to	NULL
inhibit	NULL
DNA	NULL
replication	NULL
by	NULL
direct	NULL
binding	NULL
to	NULL
PCNA	NULL
(	NULL
19-21	NULL
)	NULL
,	NULL
and	NULL
by	NULL
interacting	NULL
with	NULL
cyclin-dependent	NULL
kinases	NULL
(	NULL
22-25	NULL
)	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
the	NULL
tumor	NULL
suppressor	NULL
protein	NULL
p130/Rb2	NULL
was	NULL
found	NULL
capable	NULL
of	NULL
inhibiting	NULL
transcription	NULL
from	NULL
the	NULL
E2F1	NULL
promoter	NULL
(	NULL
7	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
pRB	NULL
was	NULL
observed	NULL
able	NULL
to	NULL
inhibit	NULL
the	NULL
E2Fl-dependent	NULL
transactivation	NULL
of	NULL
S-phase	NULL
genes	NULL
by	NULL
direct	NULL
binding	NULL
to	NULL
E2F1	NULL
(	NULL
26-28	NULL
)	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
demonstration	NULL
that	NULL
these	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
can	NULL
down-regulate	NULL
the	NULL
expression	NULL
and	NULL
activation	NULL
of	NULL
PCNA	NULL
and	NULL
E2F1	NULL
in	NULL
a	NULL
concentration-dependent	NULL
manner	NULL
suggested	NULL
that	NULL
,	NULL
in	NULL
intact	NULL
cells	NULL
,	NULL
they	NULL
may	NULL
act	NULL
in	NULL
a	NULL
parallel	NULL
manner	NULL
.	NULL

That	NULL
expectation	NULL
was	NULL
borne	NULL
out	NULL
by	NULL
the	NULL
data	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

The	NULL
tumor	NULL
suppressor	NULL
protein	NULL
p53	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
a	NULL
and	NULL
b	NULL
)	NULL
,	NULL
its	NULL
auxiliary	NULL
factor	NULL
p21/Cipl	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
c	NULL
and	NULL
d	NULL
)	NULL
,	NULL
and	NULL
the	NULL
tumor	NULL
suppressor	NULL
protein	NULL
pRb	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
g	NULL
and	NULL
A	NULL
)	NULL
,	NULL
were	NULL
all	NULL
expressed	NULL
at	NULL
20-	NULL
to	NULL
30-fold	NULL
elevated	NULL
levels	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
differentiation-induced	NULL
cells	NULL
,	NULL
remaining	NULL
at	NULL
very	NULL
low	NULL
levels	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
control	NULL
and	NULL
of	NULL
proliferation-stimulated	NULL
cells	NULL
.	NULL

p21	NULL
deviated	NULL
from	NULL
this	NULL
pattern	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
its	NULL
level	NULL
was	NULL
also	NULL
increased	NULL
to	NULL
a	NULL
significant	NULL
extent	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
|	NULL
a	NULL
0	NULL
--	NULL
--	NULL
Cbonn	NULL
)	NULL
--	NULL
)	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Schematic	NULL
outline	NULL
of	NULL
metabolic	NULL
sites	NULL
at	NULL
which	NULL
the	NULL
synthesis	NULL
of	NULL
proliferation-associated	NULL
DNA	NULL
and	NULL
mRNA	NULL
is	NULL
inhibited	NULL
by	NULL
tumor-suppressor	NULL
proteins	NULL
expressed	NULL
in	NULL
differentiation-induced	NULL
cells	NULL
.	NULL

Differentiation	NULL
Factor	NULL
Growth	NULL
Factor	NULL
pRb	NULL
4284	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

DIFFERENTIATION	NULL
REGULATORS	NULL
40	NULL
(	NULL
a	NULL
)	NULL
p53	NULL
;	NULL
cytoplasmic	NULL
||	NULL
(	NULL
b	NULL
)	NULL
p53	NULL
;	NULL
nuctear	NULL
(	NULL
e	NULL
)	NULL
_	NULL
p21	NULL
,	NULL
Cip1	NULL
;	NULL
(	NULL
d	NULL
)	NULL
p21	NULL
,	NULL
Cip1	NULL
;	NULL
nuciear	NULL
cytoptasmic	NULL
``	NULL
D	NULL
)	NULL
»	NULL
-	NULL
|E	NULL
»	NULL
||	NULL
c	NULL
D	NULL
G	NULL
o	NULL
-p21	NULL
20	NULL
L	NULL
L	NULL
L	NULL
G	NULL
D	NULL
10	NULL
F-	NULL
P	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Time-dependent	NULL
change	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
7	NULL
the	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
p53	NULL
(	NULL
a	NULL
,	NULL
b	NULL
)	NULL
,	NULL
p130/Rb2	NULL
>	NULL
o	NULL
(	NULL
e	NULL
,	NULL
f	NULL
)	NULL
,	NULL
and	NULL
pRb	NULL
(	NULL
g	NULL
,	NULL
A	NULL
)	NULL
and	NULL
of	NULL
the	NULL
auxiliary	NULL
protein	NULL
__	NULL
5	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
eo	NULL
0	NULL
10	NULL
20	NULL
so	NULL
40	NULL
so	NULL
so	NULL
°	NULL
!	NULL

°	NULL
20	NULL
30	NULL
40	NULL
so	NULL
so	NULL
0	NULL
10	NULL
20	NULL
so	NULL
40	NULL
so	NULL
so	NULL
p21/Cipl	NULL
(	NULL
c	NULL
,	NULL
d	NULL
)	NULL
in	NULL
cytoplasm	NULL
and	NULL
nuclei	NULL
of	NULL
untreated	NULL
o	NULL
-*	NULL
(	NULL
O	NULL
)	NULL
,	NULL
proliferation-stimulated	NULL
(	NULL
@	NULL
)	NULL
,	NULL
or	NULL
differentiation-	NULL
_	NULL
>	NULL
L	NULL
(	NULL
e	NULL
)	NULL
p130	NULL
;	NULL
(	NULL
f	NULL
)	NULL
-	NULL
p130	NULL
;	NULL
nuclear	NULL
|	NULL
[	NULL
(	NULL
g	NULL
)	NULL
pRb	NULL
;	NULL
cytoplasmic	NULL
||	NULL
(	NULL
h	NULL
)	NULL
pRb	NULL
;	NULL
nuclear	NULL
induced	NULL
(	NULL
0	NULL
)	NULL
ML-1	NULL
cells	NULL
.	NULL

The	NULL
values	NULL
shown	NULL
were	NULL
g	NULL
cytoplasmic	NULL
determined	NULL
by	NULL
Western	NULL
blots	NULL
normalized	NULL
to	NULL
O-time	NULL
.	NULL

m	NULL
30	NULL
-	NULL
r-	NULL
-	NULL
-	NULL
“	NULL
ppm	NULL
:	NULL
The	NULL
data	NULL
presented	NULL
in	NULL
the	NULL
panels	NULL
are	NULL
representative	NULL
[	NULL
ra	NULL
wa	NULL
I	NULL
--	NULL
r1-	NULL
‘	NULL
l	NULL
1	NULL
of	NULL
at	NULL
least	NULL
three	NULL
separate	NULL
experiments	NULL
each	NULL
.	NULL

C	NULL
b	NULL
6	NULL
D	NULL
20	NULL
|-	NULL
a	NULL
L	NULL
10	NULL
|-	NULL
L	NULL
ow	NULL
£04	NULL
a	NULL
t	NULL
a	NULL
b	NULL
cg	NULL
1	NULL
0	NULL
10	NULL
20	NULL
30	NULL
4G	NULL
50	NULL
60	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
so	NULL
eo	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
o	NULL
so	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
so	NULL
so	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
the	NULL
differentiation-induced	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4c	NULL
)	NULL
.	NULL

A	NULL
deviation	NULL
from	NULL
the	NULL
gen-	NULL
-	NULL
associated	NULL
with	NULL
the	NULL
process	NULL
of	NULL
differentiation	NULL
.	NULL

This	NULL
conclusion	NULL
is	NULL
eral	NULL
pattern	NULL
was	NULL
also	NULL
provided	NULL
by	NULL
p130/Rb2	NULL
(	NULL
Fig	NULL
.	NULL

4f	NULL
)	NULL
,	NULL
its	NULL
initial	NULL
-	NULL
further	NULL
supported	NULL
by	NULL
the	NULL
data	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

The	NULL
EMSA	NULL
analysis	NULL
nuclear	NULL
concentration	NULL
being	NULL
elevated	NULL
in	NULL
control	NULL
as	NULL
well	NULL
as	NULL
in	NULL
growth-	NULL
-	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

5a	NULL
demonstrated	NULL
that	NULL
p53	NULL
binds	NULL
to	NULL
the	NULL
PCNA	NULL
and	NULL
differentiation-induced	NULL
cells	NULL
.	NULL

That	NULL
level	NULL
increased	NULL
further	NULL
with	NULL
-	NULL
promoter	NULL
only	NULL
in	NULL
extracts	NULL
from	NULL
differentiation-induced	NULL
(	NULL
D	NULL
)	NULL
but	NULL
not	NULL
time	NULL
in	NULL
differentiation	NULL
but	NULL
decreased	NULL
in	NULL
control	NULL
and	NULL
in	NULL
growth-stimu-	NULL
-	NULL
from	NULL
proliferation-induced	NULL
(	NULL
G	NULL
)	NULL
ML-1	NULL
cells	NULL
.	NULL

That	NULL
selective	NULL
complex-lated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4f	NULL
)	NULL
.	NULL

Isolated	NULL
differentiation-associated	NULL
increases	NULL
in	NULL
the	NULL
-	NULL
ation	NULL
correlates	NULL
with	NULL
the	NULL
fact	NULL
that	NULL
p53	NULL
is	NULL
expressed	NULL
at	NULL
markedly	NULL
level	NULL
of	NULL
one	NULL
or	NULL
the	NULL
other	NULL
of	NULL
these	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
were	NULL
also	NULL
-	NULL
elevated	NULL
levels	NULL
only	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
differentiation-observed	NULL
in	NULL
diverse	NULL
other	NULL
cell	NULL
lines	NULL
(	NULL
for	NULL
examples	NULL
,	NULL
see	NULL
Refs	NULL
.	NULL

29-31	NULL
)	NULL
.	NULL

-	NULL
stimulated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

46	NULL
)	NULL
.	NULL

These	NULL
results	NULL
clearly	NULL
demonstrated	NULL
that	NULL
expression	NULL
of	NULL
these	NULL
tumor	NULL
Similarly	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5b-2	NULL
,	NULL
significant	NULL
complexation	NULL
of	NULL
p130	NULL
suppressor	NULL
proteins	NULL
and	NULL
of	NULL
the	NULL
auxiliary	NULL
protein	NULL
p21/Cipl	NULL
is	NULL
uniquely	NULL
_	NULL
with	NULL
the	NULL
E2F1	NULL
promoter	NULL
occurred	NULL
at	NULL
the	NULL
40-50	NULL
h	NULL
time	NULL
point	NULL
in	NULL
extracts	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Interaction	NULL
of	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
with	NULL
the	NULL
processivity	NULL
factor	NULL
PCNA	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
E2F1	NULL
.	NULL

Fig	NULL
.	NULL

5a	NULL
shows	NULL
the	NULL
binding	NULL
of	NULL
wild-type	NULL
p53	NULL
to	NULL
the	NULL
human	NULL
PCNA	NULL
promoter	NULL
.	NULL

Segment	NULL
-272	NULL
to	NULL
-46	NULL
(	NULL
6	NULL
)	NULL
was	NULL
labeled	NULL
with	NULL
*°P	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
ML-1	NULL
cells	NULL
untreated	NULL
(	NULL
C	NULL
)	NULL
,	NULL
treated	NULL
with	NULL
IGF-I	NULL
(	NULL
G	NULL
)	NULL
,	NULL
or	NULL
with	NULL
TNF-a	NULL
+	NULL
TGF-B1	NULL
(	NULL
D	NULL
)	NULL
.	NULL

Specificity	NULL
of	NULL
binding	NULL
was	NULL
confirmed	NULL
by	NULL
competition	NULL
with	NULL
50	NULL
%	NULL
unlabeled	NULL
probe	NULL
(	NULL
D	NULL
+	NULL
cold	NULL
50	NULL
%	NULL
)	NULL
.	NULL

The	NULL
PCNA/pS3	NULL
complex	NULL
formed	NULL
in	NULL
differentiation	NULL
was	NULL
identified	NULL
using	NULL
anti-p53	NULL
antibody	NULL
(	NULL
D	NULL
+	NULL
ap53	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

5	NULL
,	NULL
b-/	NULL
and	NULL
b-2	NULL
,	NULL
shows	NULL
p1l30/Rb2	NULL
binding	NULL
to	NULL
the	NULL
E2F1	NULL
promoter	NULL
sequence	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
ML-1	NULL
cells	NULL
untreated	NULL
(	NULL
C	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
IGF-I	NULL
(	NULL
G	NULL
)	NULL
or	NULL
TNFa	NULL
+	NULL
TGF-B1	NULL
(	NULL
D	NULL
)	NULL
for	NULL
5	NULL
h	NULL
(	NULL
b-	NULL
!	NULL
)	NULL

or	NULL
for	NULL
46	NULL
h	NULL
(	NULL
b-2	NULL
)	NULL
.	NULL

A	NULL
101-bp	NULL
Eagl	NULL
fragment	NULL
,	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
E2FI	NULL
promoter	NULL
,	NULL
was	NULL
labeled	NULL
with	NULL
*°P	NULL
and	NULL
used	NULL
as	NULL
the	NULL
probe	NULL
.	NULL

A	NULL
75	NULL
%	NULL
unlabeled	NULL
probe	NULL
was	NULL
used	NULL
to	NULL
demonstrate	NULL
the	NULL
specificity	NULL
of	NULL
binding	NULL
.	NULL

The	NULL
an-	NULL
|P	NULL
aPCNA	NULL
(	NULL
C	NULL
)	NULL
ap21/Cip1	NULL
apRb	NULL
(	NULL
d	NULL
)	NULL
«	NULL
E2F1	NULL
tibody	NULL
to	NULL
p130/Rb2	NULL
was	NULL
used	NULL
to	NULL
demonstrate	NULL
the	NULL
conn	NULL
s	NULL
ols	NULL
presence	NULL
of	NULL
p130	NULL
in	NULL
the	NULL
complex	NULL
.	NULL

Fig	NULL
.	NULL

5	NULL
,	NULL
c	NULL
and	NULL
d	NULL
,	NULL
Western	NULL
ap21/Cipt	NULL
aPCNA	NULL
aE2F1	NULL
«	NULL
pRb	NULL
shows	NULL
the	NULL
protein-protein	NULL
interactions	NULL
between	NULL
%	NULL
7	NULL
p21/Cipl-PCNA	NULL
and	NULL
pRb-E2F1	NULL
in	NULL
nuclear	NULL
extracts	NULL
+PCNA	NULL
(	NULL
300	NULL
ug	NULL
protein/sample	NULL
)	NULL
from	NULL
differentiation-stim-	NULL
+-PRb	NULL
ulated	NULL
cells	NULL
(	NULL
Lane	NULL
D	NULL
)	NULL
.	NULL

The	NULL
extracts	NULL
were	NULL
immuno-precipitated	NULL
with	NULL
either	NULL
anti-PCNA	NULL
or	NULL
anti-p21/	NULL
Cipl	NULL
(	NULL
5c	NULL
)	NULL
and	NULL
with	NULL
anti-pRb	NULL
or	NULL
anti-E2F1	NULL
(	NULL
5d	NULL
)	NULL
.	NULL

The	NULL
immune	NULL
complexes	NULL
were	NULL
collected	NULL
using	NULL
immobilized	NULL
protein	NULL
A	NULL
beads	NULL
,	NULL
and	NULL
were	NULL
probed	NULL
with	NULL
antibodies	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
p21/Cip1	NULL
,	NULL
PCNA	NULL
,	NULL
E2FI1	NULL
,	NULL
and	NULL
pRb	NULL
.	NULL

p21~	NULL
E2F	NULL
j	NULL
»	NULL
D+cold50x	NULL
G+ap53	NULL
‘	NULL
G+cold	NULL
?	NULL

5ui	NULL
G+ap130	NULL
D+cold75x	NULL
C+cold75x	NULL
C+ap130	NULL
G	NULL
G+cold75x	NULL
G+ap130	NULL
D+cold75x	NULL
D+ap130	NULL
Probe	NULL
D+ap	NULL
130	NULL
Ce	NULL
«	NULL
«	NULL
onit	NULL
:	NULL
«	NULL
#	NULL
Ca	NULL
i=	NULL
£	NULL
OE¥U	NULL
;	NULL
HZ3	NULL
|	NULL
D	NULL
C	NULL
PCNA/pS3	NULL
(	NULL
b-2	NULL
)	NULL
NRS	NULL
G	NULL
D	NULL
NRS	NULL
c	NULL
b	NULL
NRS	NULL
G	NULL
D	NULL
NRS	NULL
G	NULL
Do	NULL
4285	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

DIFFERENTIATION	NULL
REGULATORS	NULL
100	NULL
100	NULL
RR	NULL
Cel|	NULL
Number	NULL
.	NULL

.	NULL

(	NULL
c	NULL
)	NULL
(	NULL
d	NULL
)	NULL
L	NULL
[	NULL
le	NULL
Differentiated	NULL
Cells	NULL
A	NULL
T	NULL
I	NULL
1	NULL
[	NULL
a	NULL
0	NULL
I5	NULL
}	NULL
17s	NULL
©	NULL
o	NULL
UO	NULL
y-xX	NULL
UO	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
antisense	NULL
(	NULL
A5	NULL
)	NULL
and	NULL
sense	NULL
(	NULL
S	NULL
)	NULL
_	NULL
*	NULL
``	NULL
[	NULL
1	NULL
@	NULL
oligonucleotides	NULL
of	NULL
pRb	NULL
,	NULL
p53	NULL
,	NULL
and	NULL
p130	NULL
on	NULL
the	NULL
k.	NULL
``	NULL
S	NULL
number	NULL
and	NULL
the	NULL
differentiation	NULL
status	NULL
of	NULL
ML-1	NULL
cells	NULL
.	NULL

0	NULL
ts	NULL
The	NULL
antisense	NULL
(	NULL
a	NULL
and	NULL
c	NULL
)	NULL
or	NULL
sense	NULL
(	NULL
b	NULL
and	NULL
d	NULL
)	NULL
oligonu-	NULL
-A	NULL
50	NULL
|-	NULL
-|	NULL
50	NULL
C	NULL
cleotides	NULL
were	NULL
added	NULL
to	NULL
the	NULL
ML-1	NULL
cell	NULL
cultures	NULL
E	NULL
8	NULL
devoid	NULL
of	NULL
(	NULL
control	NULL
)	NULL
or	NULL
containing	NULL
the	NULL
DFs	NULL
TGF-B1	NULL
J	NULL
0	NULL
and	NULL
TNF-a	NULL
.	NULL

Cell	NULL
numbers	NULL
were	NULL
determined	NULL
by	NULL
he-	NULL
-	NULL
*-	NULL
}	NULL
{	NULL
y	NULL
mocytometer	NULL
,	NULL
and	NULL
maturation	NULL
was	NULL
determined	NULL
by	NULL
=	NULL
*-assessing	NULL
the	NULL
differentiated	NULL
morphology	NULL
.	NULL

d	NULL
(	NULL
0	NULL
)	NULL
(	NULL
b	NULL
)	NULL
o	NULL
O	NULL
-	NULL
25	NULL
|-	NULL
<	NULL
250	NULL
ye	NULL
0	NULL
$	NULL
+	NULL
RB	NULL
sa3	NULL
p130	NULL
+	NULL
RS	NULL
p53	NULL
p130	NULL
br	NULL
+	NULL
RB	NULL
p53	NULL
p130	NULL
DF	NULL
+	NULL
RMB	NULL
pB3	NULL
P130	NULL
-	NULL
0	NULL
i	NULL
un	NULL
bs	NULL
an	NULL
|	NULL
$	NULL
``	NULL
c	NULL
)	NULL
a	NULL
(	NULL
®	NULL
)	NULL
(	NULL
as	NULL
)	NULL
(	NULL
as	NULL
)	NULL
(	NULL
as	NULL
)	NULL
9	NULL
``	NULL
i	NULL
»	NULL
@	NULL
0	NULL
8	NULL
from	NULL
only	NULL
differentiation-stimulated	NULL
(	NULL
D	NULL
)	NULL
but	NULL
not	NULL
from	NULL
proliferation-	NULL
-	NULL
Acknowledgments	NULL
stimulated	NULL
(	NULL
G	NULL
)	NULL
cells	NULL
.	NULL

That	NULL
complexation	NULL
correlates	NULL
with	NULL
the	NULL
high	NULL
level	NULL
of	NULL
p130	NULL
that	NULL
,	NULL
at	NULL
this	NULL
time	NULL
interval	NULL
,	NULL
is	NULL
found	NULL
present	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
differentiation-induced	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4f	NULL
)	NULL
.	NULL

The	NULL
elevated	NULL
levels	NULL
of	NULL
p130	NULL
that	NULL
were	NULL
present	NULL
in	NULL
control	NULL
cells	NULL
and	NULL
in	NULL
proliferation-stimulated	NULL
cells	NULL
at	NULL
early	NULL
time	NULL
points	NULL
(	NULL
0-15	NULL
h	NULL
;	NULL
Fig	NULL
.	NULL

4f	NULL
)	NULL
,	NULL
likely	NULL
account	NULL
for	NULL
the	NULL
significant	NULL
extent	NULL
of	NULL
complexation	NULL
between	NULL
p130	NULL
and	NULL
E2FI1	NULL
that	NULL
occurred	NULL
at	NULL
these	NULL
time	NULL
points	NULL
(	NULL
Fig	NULL
.	NULL

5b-7	NULL
)	NULL
in	NULL
growth-induced	NULL
as	NULL
well	NULL
as	NULL
in	NULL
differentiation-induced	NULL
cells	NULL
.	NULL

It	NULL
seems	NULL
that	NULL
early	NULL
transcription	NULL
from	NULL
the	NULL
E2F1	NULL
promoter	NULL
is	NULL
suppressed	NULL
in	NULL
both	NULL
growth	NULL
and	NULL
differentiation	NULL
with	NULL
growth-associated	NULL
E2F1	NULL
expression	NULL
being	NULL
allowed	NULL
only	NULL
at	NULL
later	NULL
time	NULL
points	NULL
,	NULL
when	NULL
the	NULL
p130	NULL
concentration	NULL
declines	NULL
to	NULL
a	NULL
low	NULL
level	NULL
(	NULL
Fig	NULL
.	NULL

4f	NULL
versus	NULL
Fig	NULL
.	NULL

2e	NULL
)	NULL
.	NULL

Analogous	NULL
to	NULL
the	NULL
differentiation-associated	NULL
inhibition	NULL
of	NULL
the	NULL
PCNA	NULL
promoter	NULL
by	NULL
p53	NULL
and	NULL
of	NULL
the	NULL
E2F1	NULL
promoter	NULL
by	NULL
p130	NULL
,	NULL
direct	NULL
binding	NULL
of	NULL
p21/Cip	NULL
!	NULL

to	NULL
PCNA	NULL
(	NULL
Fig	NULL
.	NULL

5¢c	NULL
)	NULL
and	NULL
of	NULL
pRb	NULL
to	NULL
E2F1	NULL
(	NULL
Fig	NULL
.	NULL

5d	NULL
)	NULL
occurred	NULL
only	NULL
in	NULL
differentiation-induced	NULL
cells	NULL
,	NULL
such	NULL
binding	NULL
contributing	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
G	NULL
,	NULL
-S-associated	NULL
DNA	NULL
synthesis	NULL
and	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
c	NULL
and	NULL
f	NULL
;	NULL
Refs	NULL
.	NULL

6	NULL
,	NULL
7	NULL
,	NULL
24-26	NULL
)	NULL
.	NULL

To	NULL
gain	NULL
additional	NULL
experimental	NULL
support	NULL
for	NULL
the	NULL
regulatory	NULL
role	NULL
that	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
are	NULL
indicated	NULL
to	NULL
play	NULL
in	NULL
the	NULL
process	NULL
of	NULL
cell	NULL
differentiation	NULL
,	NULL
sense	NULL
and	NULL
antisense	NULL
oligonucleotides	NULL
of	NULL
p53	NULL
,	NULL
p130	NULL
,	NULL
and	NULL
pRb	NULL
were	NULL
added	NULL
to	NULL
ML-1	NULL
cells	NULL
untreated	NULL
(	NULL
control	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
the	NULL
DFs	NULL
TGF-B1	NULL
and	NULL
TNF-	NULL
«	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
a	NULL
significant	NULL
reduction	NULL
in	NULL
the	NULL
number	NULL
of	NULL
differentiated	NULL
cells	NULL
was	NULL
obtained	NULL
only	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
antisense	NULL
oligonucleotides	NULL
of	NULL
p53	NULL
,	NULL
p130	NULL
,	NULL
and	NULL
pRb	NULL
,	NULL
with	NULL
their	NULL
number	NULL
being	NULL
decreased	NULL
by	NULL
44	NULL
,	NULL
68	NULL
,	NULL
and	NULL
63	NULL
%	NULL
,	NULL
respectively	NULL
.	NULL

No	NULL
significant	NULL
changes	NULL
in	NULL
the	NULL
number	NULL
of	NULL
differentiated	NULL
cells	NULL
occurred	NULL
in	NULL
cultures	NULL
treated	NULL
with	NULL
the	NULL
coresponding	NULL
sense	NULL
oligonucleotides	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
DF	NULL
,	NULL
the	NULL
cells	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
treatment	NULL
with	NULL
antisense	NULL
oligonu-cleotides	NULL
,	NULL
which	NULL
supports	NULL
the	NULL
indication	NULL
that	NULL
their	NULL
action	NULL
pertains	NULL
to	NULL
the	NULL
differentiation	NULL
process	NULL
.	NULL

By	NULL
participating	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
PCNA-dependent	NULL
and	NULL
E2F1-dependent	NULL
G	NULL
,	NULL
-S	NULL
transit	NULL
,	NULL
the	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
are	NULL
indicated	NULL
to	NULL
uncouple	NULL
growth	NULL
from	NULL
differentiation	NULL
(	NULL
32	NULL
)	NULL
,	NULL
allowing	NULL
entry	NULL
into	NULL
the	NULL
maturation	NULL
path	NULL
.	NULL

Where	NULL
this	NULL
function	NULL
of	NULL
the	NULL
tumor	NULL
suppressor	NULL
proteins	NULL
is	NULL
impaired	NULL
,	NULL
sustained	NULL
proliferation	NULL
at	NULL
a	NULL
stage	NULL
of	NULL
incomplete	NULL
maturation	NULL
is	NULL
expected	NULL
to	NULL
ensue	NULL
,	NULL
that	NULL
condition	NULL
being	NULL
a	NULL
prime	NULL
characteristic	NULL
of	NULL
the	NULL
cancer	NULL
cell	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Bristol-Myers	NULL
Squibb	NULL
(	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
for	NULL
providing	NULL
TGF-B1	NULL
and	NULL
to	NULL
Asahi	NULL
Chemical	NULL
Industry	NULL
(	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
for	NULL
TNF-a	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Swati	NULL
P.	NULL
Deb	NULL
(	NULL
University	NULL
of	NULL
Texas	NULL
Health	NULL
Science	NULL
Center	NULL
at	NULL
San	NULL
Antonio	NULL
,	NULL
TX	NULL
)	NULL
for	NULL
providing	NULL
PCNA-promoter	NULL
DNA	NULL
and	NULL
David	NULL
G.	NULL
Johnson	NULL
(	NULL
University	NULL
of	NULL
Texas	NULL
M.	NULL
D.	NULL
Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
Science	NULL
Park-Research	NULL
Division	NULL
,	NULL
Smithville	NULL
,	NULL
TX	NULL
)	NULL
for	NULL
donating	NULL
E2F-1-promoter	NULL
DNA	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Bos	NULL
,	NULL
T.	NULL
J.	NULL
Oncogenes	NULL
and	NULL
cell	NULL
growth	NULL
.	NULL

Adv	NULL
.	NULL

Exp	NULL
.	NULL

Med	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
327	NULL
:	NULL
45-49	NULL
,	NULL
1992	NULL
.	NULL

2	NULL
.	NULL

Levine	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

The	NULL
tumor	NULL
suppressor	NULL
genes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
62	NULL
:	NULL
623-651	NULL
,	NULL
1993	NULL
.	NULL

3	NULL
.	NULL

Bergh	NULL
,	NULL
G.	NULL
,	NULL
Ehinger	NULL
,	NULL
M.	NULL
,	NULL
Olofsson	NULL
,	NULL
T.	NULL
,	NULL
Baldetorp	NULL
,	NULL
B.	NULL
,	NULL
Johnsson	NULL
,	NULL
E.	NULL
,	NULL
Brycke	NULL
,	NULL
H.	NULL
,	NULL
Lindgren	NULL
,	NULL
G.	NULL
,	NULL
Olsson	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
Gullberg	NULL
,	NULL
U.	NULL
Altered	NULL
expression	NULL
of	NULL
the	NULL
retinoblastoma	NULL
tumor-suppressor	NULL
gene	NULL
in	NULL
leukemic	NULL
cell	NULL
lines	NULL
inhibits	NULL
induction	NULL
of	NULL
differentiation	NULL
but	NULL
not	NULL
Gl-accumulation	NULL
.	NULL

Blood	NULL
,	NULL
89	NULL
:	NULL
2938-2950	NULL
,	NULL
1997	NULL
.	NULL

4	NULL
.	NULL

Zhu	NULL
,	NULL
Y-M.	NULL
,	NULL
Bradbury	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
Russell	NULL
,	NULL
N.	NULL
H.	NULL
Wild-type	NULL
p53	NULL
is	NULL
required	NULL
for	NULL
apoptosis	NULL
induced	NULL
by	NULL
growth	NULL
factor	NULL
deprivation	NULL
in	NULL
factor-dependent	NULL
leukaemic	NULL
cells	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
69	NULL
:	NULL
468-472	NULL
,	NULL
1994	NULL
.	NULL

5	NULL
.	NULL

Baldi	NULL
,	NULL
A.	NULL
,	NULL
Boccia	NULL
,	NULL
V.	NULL
,	NULL
Claudio	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
De	NULL
Luca	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Giordano	NULL
,	NULL
A.	NULL
Genomic	NULL
structure	NULL
of	NULL
the	NULL
human	NULL
retinoblastoma-related	NULL
Rb2/p730	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
:	NULL
4629-4632	NULL
,	NULL
1996	NULL
.	NULL

6	NULL
.	NULL

Shivakumar	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
Brown	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Deb	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Deb	NULL
,	NULL
S.	NULL
P.	NULL
Wild-type	NULL
human	NULL
p53	NULL
transactivates	NULL
the	NULL
human	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
:	NULL
6785-6793	NULL
,	NULL
1995	NULL
.	NULL

7	NULL
.	NULL

Johnson	NULL
,	NULL
D.	NULL
G.	NULL
Regulation	NULL
of	NULL
E2F-/	NULL
gene	NULL
expression	NULL
by	NULL
p130	NULL
(	NULL
Rb2	NULL
)	NULL
and	NULL
D-type	NULL
cyclin	NULL
kinase	NULL
activity	NULL
.	NULL

Oncogene	NULL
,	NULL
77	NULL
:	NULL
1685-1692	NULL
,	NULL
1995	NULL
.	NULL

8	NULL
.	NULL

Li	NULL
,	NULL
Z-R.	NULL
,	NULL
Hromchak	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Bloch	NULL
,	NULL
A	NULL
.	NULL

Differential	NULL
expression	NULL
of	NULL
proteins	NULL
regulating	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
growth	NULL
vs.	NULL
differentiation	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
1356	NULL
;	NULL
149-159	NULL
,	NULL
1997	NULL
.	NULL

9	NULL
.	NULL

Honma	NULL
,	NULL
Y.	NULL
,	NULL
Honma	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Bloch	NULL
,	NULL
A.	NULL
Mechanisms	NULL
of	NULL
interaction	NULL
between	NULL
antineo-plastic	NULL
agents	NULL
and	NULL
natural	NULL
differentiation	NULL
factors	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
human	NULL
leukemic	NULL
cell	NULL
maturation	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
46	NULL
:	NULL
6311-6315	NULL
,	NULL
1986	NULL
.	NULL

10	NULL
.	NULL

Takeda	NULL
,	NULL
K.	NULL
,	NULL
Minowada	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Bloch	NULL
,	NULL
A.	NULL
Kinetics	NULL
of	NULL
appearance	NULL
of	NULL
differentiation-associated	NULL
characteristics	NULL
in	NULL
ML-1	NULL
,	NULL
a	NULL
line	NULL
of	NULL
human	NULL
myeloblastic	NULL
leukemia	NULL
cells	NULL
,	NULL
after	NULL
treatment	NULL
with	NULL
12-0-tetradecanoylphorbol-13-acetate	NULL
,	NULL
dimethyl	NULL
sulfoxide	NULL
,	NULL
or	NULL
arabinofuranosylcytosine	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
42	NULL
:	NULL
5152-5158	NULL
,	NULL
1982	NULL
.	NULL

11	NULL
.	NULL

Kelman	NULL
,	NULL
Z.	NULL
PCNA	NULL
:	NULL
structure	NULL
,	NULL
functions	NULL
and	NULL
interactions	NULL
.	NULL

Oncogene	NULL
,	NULL
74	NULL
:	NULL
629-640	NULL
,	NULL
1997	NULL
.	NULL

12	NULL
.	NULL

Adams	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
and	NULL
Kaelin	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
Jr.	NULL
Transcriptional	NULL
control	NULL
by	NULL
E2F	NULL
.	NULL

Semin	NULL
.	NULL

Cancer	NULL
Biol	NULL
.	NULL

,	NULL
6	NULL
:	NULL
99-108	NULL
,	NULL
1995	NULL
.	NULL

13	NULL
.	NULL

Krek	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
DeCaprio	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

Cell	NULL
synchronization	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

,	NULL
254	NULL
:	NULL
114-124	NULL
,	NULL
1995	NULL
.	NULL

14	NULL
.	NULL

Kastan	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Radin	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Kuerbitz	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Onyekwere	NULL
,	NULL
O.	NULL
,	NULL
Wolkow	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Civin	NULL
,	NULL
C.	NULL
I.	NULL
,	NULL
Stone	NULL
,	NULL
K.	NULL
D.	NULL
,	NULL
Woo	NULL
,	NULL
T.	NULL
,	NULL
Ravindranath	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Craig	NULL
,	NULL
R.	NULL
W.	NULL
Levels	NULL
of	NULL
p53	NULL
protein	NULL
increase	NULL
with	NULL
maturation	NULL
in	NULL
human	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
:	NULL
4279-4286	NULL
,	NULL
1991	NULL
.	NULL

15	NULL
.	NULL

Mercer	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Shields	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Lin	NULL
,	NULL
D.	NULL
,	NULL
Appella	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Ullrich	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

Growth	NULL
suppression	NULL
induced	NULL
by	NULL
wild-type	NULL
p53	NULL
protein	NULL
is	NULL
accompanied	NULL
by	NULL
selective	NULL
down-regulation	NULL
of	NULL
proliferating-cell	NULL
nuclear	NULL
antigen	NULL
expression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
88	NULL
:	NULL
1958-1962	NULL
,	NULL
1991	NULL
.	NULL

4286	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

DIFFERENTIATION	NULL
REGULATORS	NULL
.	NULL

Jackson	NULL
,	NULL
P.	NULL
,	NULL
Ridgway	NULL
,	NULL
P.	NULL
,	NULL
Rayner	NULL
,	NULL
J.	NULL
,	NULL
Noble	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Braithwaite	NULL
,	NULL
A.	NULL
Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
PCNA	NULL
promoter	NULL
by	NULL
p53	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
203	NULL
:	NULL
133-140	NULL
,	NULL
1994.	NULL
.	NULL

Morris	NULL
,	NULL
G.	NULL
F.	NULL
,	NULL
Bischoff	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
and	NULL
Mathews	NULL
,	NULL
M.	NULL
B.	NULL
Transcriptional	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
proliferating-cell	NULL
nuclear	NULL
antigen	NULL
promoter	NULL
by	NULL
p53	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
:	NULL
895-899	NULL
,	NULL
1996.	NULL
.	NULL

El-Deiry	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Tokino	NULL
,	NULL
T.	NULL
,	NULL
Velculescu	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
Levy	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Parsons	NULL
,	NULL
R.	NULL
,	NULL
Trent	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Lin	NULL
,	NULL
D.	NULL
,	NULL
Mercer	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Kinzler	NULL
,	NULL
K.	NULL
W.	NULL
,	NULL
and	NULL
Vogelstein	NULL
,	NULL
B.	NULL
Waf1	NULL
,	NULL
a	NULL
potential	NULL
mediator	NULL
of	NULL
p53	NULL
tumor	NULL
suppression	NULL
.	NULL

Cell	NULL
,	NULL
75	NULL
:	NULL
817-825	NULL
,	NULL
1993	NULL
.	NULL

Waga	NULL
,	NULL
S.	NULL
,	NULL
Hannon	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Beach	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Stillman	NULL
,	NULL
B	NULL
.	NULL

The	NULL
p21	NULL
inhibitor	NULL
of	NULL
cyclin-dependent	NULL
kinases	NULL
controls	NULL
DNA	NULL
replication	NULL
by	NULL
interaction	NULL
with	NULL
PCNA	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
369	NULL
:	NULL
574-578	NULL
,	NULL
1994	NULL
.	NULL

Flores-Rozas	NULL
,	NULL
H.	NULL
,	NULL
Kelman	NULL
,	NULL
Z.	NULL
,	NULL
Dean	NULL
,	NULL
F.	NULL
B.	NULL
,	NULL
Pan	NULL
,	NULL
Z.	NULL
Q.	NULL
,	NULL
Harper	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Elledge	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
O'Donnell	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Hurwitz	NULL
,	NULL
J.	NULL
Cdk-interacting	NULL
protein	NULL
1	NULL
directly	NULL
binds	NULL
with	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
and	NULL
inhibits	NULL
DNA	NULL
replication	NULL
catalyzed	NULL
by	NULL
the	NULL
DNA	NULL
polymerase	NULL
8	NULL
holoenzyme	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
97	NULL
:	NULL
8655-8659	NULL
,	NULL
1994	NULL
.	NULL

Pan	NULL
,	NULL
Z.	NULL
Q.	NULL
,	NULL
Reardon	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Li	NULL
,	NULL
L.	NULL
,	NULL
Flores-Rozas	NULL
,	NULL
H.	NULL
,	NULL
Legerski	NULL
,	NULL
R.	NULL
,	NULL
Sancar	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Hurwitz	NULL
,	NULL
J.	NULL
Inhibition	NULL
of	NULL
nucleotide	NULL
excision	NULL
repair	NULL
by	NULL
the	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
p21	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
270	NULL
:	NULL
22008-22016	NULL
,	NULL
1995	NULL
.	NULL

Strausfeld	NULL
,	NULL
U.	NULL
P.	NULL
,	NULL
Howell	NULL
,	NULL
M.	NULL
,	NULL
Rempel	NULL
,	NULL
R.	NULL
,	NULL
Maller	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Hunt	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Blow	NULL
,	NULL
J.	NULL
J.	NULL
Cipl	NULL
blocks	NULL
the	NULL
initiation	NULL
of	NULL
DNA	NULL
replication	NULL
in	NULL
Xenopus	NULL
extracts	NULL
by	NULL
inhibition	NULL
of	NULL
cyclin-dependent	NULL
kinases	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
4	NULL
:	NULL
876-883	NULL
,	NULL
1994	NULL
.	NULL

Harper	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Adami	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Wei	NULL
,	NULL
N.	NULL
,	NULL
Keyomarsi	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Elledge	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

The	NULL
p21	NULL
Cdk-interacting	NULL
protein	NULL
Cipl	NULL
is	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
G1	NULL
cyclin-dependent	NULL
kinases	NULL
.	NULL

Cell	NULL
,	NULL
75	NULL
:	NULL
805-816	NULL
,	NULL
1993	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

4287	NULL
Chen	NULL
,	NULL
J.	NULL
,	NULL
Jackson	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
Kirschner	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
and	NULL
Dutta	NULL
,	NULL
A	NULL
.	NULL

Separate	NULL
domains	NULL
of	NULL
p21	NULL
involved	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
Cdk	NULL
kinase	NULL
and	NULL
PCNA	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
374	NULL
:	NULL
386-395	NULL
,	NULL
1995	NULL
.	NULL

Luo	NULL
,	NULL
Y.	NULL
,	NULL
Hurwitz	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Massague	NULL
,	NULL
J.	NULL
Cell-cycle	NULL
inhibition	NULL
by	NULL
independent	NULL
CDK	NULL
and	NULL
PCNA	NULL
binding	NULL
domains	NULL
in	NULL
p21Cipl	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
375	NULL
:	NULL
159-161	NULL
,	NULL
1995	NULL
.	NULL

Chellappan	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
Hiebert	NULL
,	NULL
S.	NULL
,	NULL
Mudryj	NULL
,	NULL
M.	NULL
,	NULL
Horowitz	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
The	NULL
E2F	NULL
transcription	NULL
factor	NULL
is	NULL
a	NULL
cellular	NULL
target	NULL
for	NULL
the	NULL
RB	NULL
protein	NULL
.	NULL

Cell	NULL
,	NULL
65	NULL
:	NULL
1053-1061	NULL
,	NULL
1991	NULL
.	NULL

DeGregori	NULL
,	NULL
J.	NULL
,	NULL
Kowalik	NULL
,	NULL
T..	NULL
and	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
Cellular	NULL
targets	NULL
for	NULL
activation	NULL
by	NULL
the	NULL
E2F1	NULL
transcription	NULL
factor	NULL
include	NULL
DNA	NULL
synthesis-	NULL
and	NULL
G1/S-regulatory	NULL
genes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
:	NULL
4215-4224	NULL
,	NULL
1995	NULL
.	NULL

Helin	NULL
,	NULL
K.	NULL
,	NULL
Harlow	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
and	NULL
Fattaey	NULL
,	NULL
A.	NULL
L.	NULL
I.	NULL
Inhibition	NULL
of	NULL
E2F-1	NULL
transactivation	NULL
by	NULL
direct	NULL
binding	NULL
of	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
73	NULL
:	NULL
6501-6508	NULL
,	NULL
1993	NULL
.	NULL

Almog	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Rotter	NULL
,	NULL
V.	NULL
Involvement	NULL
of	NULL
p53	NULL
in	NULL
cell	NULL
differentiation	NULL
and	NULL
development	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
1333	NULL
:	NULL
FI-F27	NULL
,	NULL
1997	NULL
.	NULL

Gartel	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Serfas	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
and	NULL
Tyner	NULL
,	NULL
A.	NULL
L.	NULL
p21	NULL
-negative	NULL
regulator	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
213	NULL
:	NULL
138-149	NULL
,	NULL
1996	NULL
.	NULL

Sidle	NULL
,	NULL
A.	NULL
,	NULL
Palaty	NULL
,	NULL
C.	NULL
,	NULL
Dirks	NULL
,	NULL
P.	NULL
,	NULL
Wiggan	NULL
,	NULL
O.	NULL
,	NULL
Kiess	NULL
,	NULL
M.	NULL
,	NULL
Gill	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Wong	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
and	NULL
Hamel	NULL
P.	NULL
A	NULL
.	NULL

Activity	NULL
of	NULL
the	NULL
retinoblastoma	NULL
family	NULL
proteins	NULL
,	NULL
pRB	NULL
,	NULL
p107	NULL
,	NULL
and	NULL
p130	NULL
,	NULL
during	NULL
cellular	NULL
proliferation	NULL
and	NULL
differentiation	NULL
.	NULL

Crit	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
37	NULL
:	NULL
237-271	NULL
,	NULL
1996	NULL
.	NULL

Sachs	NULL
,	NULL
L.	NULL
Constitutive	NULL
uncoupling	NULL
of	NULL
pathways	NULL
of	NULL
gene	NULL
expression	NULL
that	NULL
control	NULL
growth	NULL
and	NULL
differentiation	NULL
in	NULL
myeloid	NULL
leukemia	NULL
:	NULL
a	NULL
model	NULL
for	NULL
the	NULL
origin	NULL
and	NULL
progression	NULL
of	NULL
malignancy	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
77	NULL
:	NULL
6152-6156	NULL
,	NULL
1980	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Tumor	NULL
Suppressor	NULL
Proteins	NULL
as	NULL
Regulators	NULL
of	NULL
Cell	NULL
Differentiation	NULL
Zhan-Rong	NULL
Li	NULL
,	NULL
Rosemary	NULL
Hromchak	NULL
,	NULL
Anuradha	NULL
Mudipalli	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
1998	NULL
;	NULL
58:4282-4287	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
9/4282	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/58/19/4282	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1998	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

